Twitxy Saved

Max Swiergol | Research-Based Health

Verified account This account is verified. Learn more

@xthemaxdose

🩺 Medical Student | Evidence-Based Medicine
🧬 Innovation • Longevity • Optimization
📚 The New Research Your Doctor May Have Missed
linktr.ee/maxdose Joined August 2026
6 Following 972 Followers 47 Posts

Latest posts 5

Pinned post

Max Swiergol | Research-Based Health Verified account @xthemaxdose
The University of Arkansas just launched the 1st U.S. based injectable BPC-157 Randomized Controlled Trial for tissue healing.

They’re studying post-rotator cuff surgery healing through objective measures like strength testing, MRI, and range of motion. Also patient reported questionnaires on recovery (PROMs).

This is what the science community and physicians needed.

Enrollment starts Early 2027.
First data likely to be seen Early 2028.

I will keep you updated.

clinicaltrials.gov/study/NCT07803…

#bpc #bpc157 #peptide #peptides #science #research
58 replies 122 reposts 1.1K likes 984K views View on X
Max Swiergol | Research-Based Health Verified account @xthemaxdose
Here's the biggest medical news this week:

1. There's a new Theranos-style company called Helios where they test 1000+ markers from a single drop of blood, intended to be done at home. Apparently they'll tell you how fast your organs are aging and your risk of over 200 diseases. The technology has real published science behind it. Launch is expected in 2027.

2. The FDA approved a powerful new breast cancer med that cut the risk of progression or death by 62% when combined with another cancer med, everolimus. It also nearly doubled the time it took before the cancer began to worsen (ER+/HER2−, ESR1-mutated advanced breast cancer).

3. The world's #1 cause of cancer death (lung cancer) just got an accelerated FDA approval for a med that, in the hardest-to-treat group, caused almost 1 in 3 patients' tumors to shrink at least 30% or disappear altogether (neladalkib, ALK+ non-small cell lung cancer).

4. A Phase 2 trial added a muscle-preserving med called trevogrumab to a GLP-1 called semaglutide. After a full year, it cut lean mass loss by about 42% compared to the GLP-1 alone.

5. Researchers successfully tested a vaccine for an aggressive type of blood cancer (AML) and it cut the risk of death by 41%. Median survival increased from 14.7 to 24 months. It's for patients who already have the cancer, so it's not preventative.

#research #news
Max Swiergol | Research-Based Health Verified account @xthemaxdose
BREAKING: This is the first time we’re seeing a company prescribe peptides based on your own individual lab values, not anyone else’s.

Their AI is nuts too. Literally takes important biomarkers and cross-examines them to fix specific health problems. This in combo with choosing which peptides might be good for you is actually really cool.

Gonna be neat to track peptide progress with your own lab values over time. Will make for a much safer approach to longevity.
Superpower Verified account @superpower Oct 30
ANNOUNCING: Superpower Peptides.

Prescription peptide care, connected with your blood testing.

For the first time, Superpower brings prescribed peptide treatments together with membership, beginning with BPC-157, TB-500 and MOTS-c.

Each one comes with:

- Treatment prescribed by licensed providers
- Comprehensive blood testing
- Clinical evaluation
- Third-party testing
- Regular check-ins and lab monitoring
- Active ingredients from FDA-registered facilities
- Prescriptions filled by US-licensed pharmacies

Because access to peptides has often outpaced guidance.

Your health history, goals and baseline bloodwork are reviewed by a licensed clinician, who can then monitor your health throughout treatment.

We’ve been preparing for this moment.

Your can start your blood test today, and at the end of November, we’re bringing peptides to you.

Pre-orders are open now:

superpower.com/peptides
View quoted post on X
44 replies 98 reposts 2.3K likes 206K views View on X
Max Swiergol | Research-Based Health Verified account @xthemaxdose
NEW RESEARCH: A clinical trial tested a chemical cousin of DMT for treatment-resistant depression and the 8mg group had 26% of participants in remission after 29 days.

Most patients were able to go home in just two hours.

The control group was a low dose of the same drug, where 8% saw remission in the same time frame.
Max Swiergol | Research-Based Health Verified account @xthemaxdose
One of the world's biggest cancer conferences is happening right now. Here are 5 breakthroughs they're talking about:

1. The world's leading cause of cancer death (lung cancer) now has a therapy that cut the risk of death by 58%, moving median survival from 12.7 to 21.1 months (small cell lung cancer).

2. A new personalized therapy for Melanoma can train the immune system in cancer patients and alongside a common cancer med, it cut the risk of recurrence or death by 42%.

3. A therapy has been FDA approved to allow certain people with a subset of rectal cancers to skip chemo, radiation, and surgery. Around half of patients so far were cancer free over a year later. Colorectal cancer is the deadliest cancer in Americans under 50.

4. Chinese researchers presented data on a new therapy for breast cancer where it more than doubled the time before the cancer began to worsen.

5. Another huge therapy saw median survival increase by almost 50% in a specific mutated type of lung cancer, while also lowering decreasing severe side effects. (NSCLC type)

See sources below.